Eliav Barr, M.D., joined the Veracyte board of directors in August 2022. Dr. Barr built his distinguished career at Merck Research Laboratories (MRL), a division of Merck & Co., Inc., a multinational pharmaceutical company, where he has served as Head of Global Clinical Development and Chief Medical Officer since April 2022.

Muna Bhanji, R.Ph., joined the Veracyte board of directors in March 2021, bringing more than 30 years of strategic and operational experience in the biopharmaceutical industry with a proven track record of commercial leadership, growth and value creation.

John L. Bishop began serving as a member of our board of directors in December 2014, and was subsequently appointed Lead Independent Director in December 2016.

Karin Eastham has served as a member Veracyte’s board of directors since December 2012. From May 2004 to September 2008, Ms. Eastham served as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees, of the Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research.

Robert S. Epstein, M.D., M.S., has served on Veracyte’s board of directors since 2015, including becoming Chairman in 2023, and has served as a strategic consultant to life sciences companies since 2013.

Jens Holstein has 25 years of financial and management expertise, spanning an array of global life science businesses.

Evan Jones began serving as a member of our board in 2008. He has served as Managing Member of jVen Capital, LLC, a life sciences investment company, since 2007.

Marc Stapley became Chief Executive Officer of Veracyte on June 1, 2021, and also serves on the company’s board of directors.